Navigation Links
Medivation Completes Enrollment of Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
Date:12/17/2008

velop and commercialize Dimebon for the treatment of Alzheimer's and Huntington's diseases. With Pfizer, the Company is conducting a broad Dimebon clinical development program, including a pivotal and confirmatory Phase 3 trial, known as the CONNECTION study, in patients with mild-to-moderate Alzheimer's disease. The program also includes additional trials planned to begin next year in Alzheimer's disease, as well as further development of Dimebon in patients with mild-to-moderate Huntington's disease. In addition, a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer is ongoing. For more information, please visit us at http://www.medivation.com.

This press release contains forward-looking statements, including statements regarding the timing and expected dosing regimen of Phase 3 trials of MDV3100, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Medivation's actual results to differ significantly from those projected, including, without limitation, risks related to progress, timing and results of Medivation's clinical trials, difficulties or delays in obtaining regulatory approval, enrollment of patients in Medivation's clinical trials, partnering of Medivation's product candidates, including Medivation's collaborative relationship with Pfizer, manufacturing of Medivation's product candidates, competition with Medivation's product candidates should they receive marketing approval, the adequacy of Medivation's financial resources, unanticipated expenditures or liabilities, intellectual property matters, and other risks detailed in
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
2. Medivations Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimers Disease Patients, Resulting in Reduced Caregiver Distress
3. Medivations Dimebon(TM) Significantly Improved Daily Function in Alzheimers Disease Patients, Resulting in Reduced Need for Caregiver Assistance
4. Medivations Dimebon(TM) Significantly Improved Thinking and Memory in Alzheimers Disease Patients Over One Year
5. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
6. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting
7. Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimers Disease
8. Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntingtons Disease
9. Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntingtons Disease
10. Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimers Disease
11. Medivation Presents Positive New Data on Dimebons Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 20, 2014 /CNW Telbec/ - KLOX Technologies Inc. ("KLOX" ... appointments: Todd Martensen has ... created role of Chief Commercial Officer, to oversee KLOX,s ... photoconverter gel for the treatment of chronic and other ... recently approved in Europe . Mr. ...
(Date:11/21/2014)... Michael DeMarco (42) erinnert sich ... Februar 2014 zugetragen hat. Seine Tochter Aly Demarco (13) ... Video - http://youtu.be/5cVoMCe0uiE „Man ... Training zu machen", erzählt Michael DeMarco . „Meine ... begeisterte Anhänger der CrossFit-Trainingsmethode. Ich war auf dem Fahrrad, ...
(Date:11/21/2014)... 2014   Coqui RadioPharmaceuticals Corp. , a medical ... producer of Molybdenum-99 (Mo-99), is proud to announce it ... to design its Medical Isotope Production Facility (MIPF) in ... parent isotope of Technetium-99, which is used in 80 ... passed legislation making it a national priority to produce ...
Breaking Medicine Technology:KLOX Technologies announces executive appointments 2KLOX Technologies announces executive appointments 3KLOX Technologies announces executive appointments 4Tochter rettet Vater durch Herz-Lungen-Wiederbelebung vor plötzlichem Herztod 2Tochter rettet Vater durch Herz-Lungen-Wiederbelebung vor plötzlichem Herztod 3Coqui RadioPharmaceuticals Inks Deal With INVAP 2
... 2011  Quest Diagnostics Incorporated (NYSE: DGX ), ... services, today announced that its Board of Directors has ... effective immediately. Including Mr. Ring, the Board has nine ... of C. R. Bard, Inc., a leading multinational developer, ...
... Dec. 7, 2011 Aoxing Pharmaceutical (NYSE Amex: ... pharmaceutical company focusing on research, development, manufacturing and ... today announced that its operating subsidiary in China, ... three-way financing agreement with Shijiazhuang Construction Investment Group ...
Cached Medicine Technology:Quest Diagnostics Adds Timothy M. Ring to Board of Directors 2Aoxing Pharmaceutical Company Announces $3.2 Million Financing 2Aoxing Pharmaceutical Company Announces $3.2 Million Financing 3
(Date:11/22/2014)... A petition seeking a ban on ... in minimally-invasive hysterectomies and fibroid removal surgeries has gained ... October, Bernstein Liebhard LLP reports. According to Change.org, ... 21st, 2014. That represents an increase of 456 signatures ... to the campaign.* , The campaign to ban uterine ...
(Date:11/22/2014)... November 22, 2014 This month has been ... because it has received many positive reviews from some renowned ... of its products by launching a new selection of wonderful ... global customers can enjoy free shipping and up to an ... Stylish ladies can always find the most suitable dress at ...
(Date:11/22/2014)... Sandbridge Capital, a private equity ... consumer brand sector, acquired a minority stake in ... to help fund BackJoy’s global growth and accelerate ... proprietary apparel and footwear lines. Sandbridge Capital Managing ... Directors. , BackJoy is a high-growth health and ...
(Date:11/22/2014)... November 22, 2014 A Xarelto lawsuit has ... who is seeking $10 million in damages from the makers ... According to the lawsuit, the woman began using Xarelto in ... alleges in her lawsuit she suffered life-threatening bleeding in July ... injuries, pain, suffering and emotional distress. The lawsuit purports that ...
(Date:11/22/2014)... Nov. 21, 2014 (HealthDay News) -- The widely used ... death and hospitalization among patients who have the heart ... failure, a new study finds. Atrial fibrillation is ... linked to a rise in risk for stroke among ... a century to help treat irregular heartbeat, the authors ...
Breaking Medicine News(10 mins):Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 2Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 3Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 4Health News:Sexy Wedding Dresses with Special Discounts Launched by Angeldress.co.uk 2Health News:Sandbridge Capital Acquires a Minority Stake in BackJoy 2Health News:Sandbridge Capital Acquires a Minority Stake in BackJoy 3Health News:Xarelto Lawsuit News: Woman Seeks $10 Million in Damages For Alleged Bleeding Side-Effect Due To Xarelto Use 2Health News:Xarelto Lawsuit News: Woman Seeks $10 Million in Damages For Alleged Bleeding Side-Effect Due To Xarelto Use 3Health News:Xarelto Lawsuit News: Woman Seeks $10 Million in Damages For Alleged Bleeding Side-Effect Due To Xarelto Use 4Health News:Treating Irregular Heartbeat With Digoxin May Come With Risks 2Health News:Treating Irregular Heartbeat With Digoxin May Come With Risks 3
... -- The use of long-distance video and data hookups to ... provides the same level of care as having everyone in ... at the Canadian Stroke Congress. The study found that ... Telestroke received an important stroke drug, tPA, at the same ...
... Gordon HealthDay Reporter , MONDAY, Oct. 3 (HealthDay ... sexually transmitted human papillomavirus (HPV) rose dramatically over two decades, ... these types of tumors might become the leading form of ... 1984 and 1989, just 16.3 percent of oral cancer samples ...
... , MONDAY, Oct. 3 (HealthDay News) -- In Utah, ... rate similar to those suspected of adult homicide, and they ... abuse homicide offenders are those who have failed to care ... ranks as one of the top five causes of childhood ...
... Sinai School of Medicine have found that $6.7 billion was ... medications in primary care, with 86 percent of that cost ... cholesterol. The findings are published in a research letter in ... Internal Medicine , one of the JAMA/Archives journals. ...
... cancer patients are given the choice, they are significantly more ... quality of life six months after treatment, compared to a ... scientific session, October 5, 2011, at the 53rd Annual Meeting ... finding challenges the perception that older cancer patients do not ...
... TORONTO, Ont., Oct. 3, 2011Studies that examined the possible link ... it,s impossible to reach a firm conclusion about the controversial ... found the blockages known as chronic cerebrospinal venous insufficiency, or ... than those who do not. But a team of ...
Cached Medicine News:Health News:Telestroke the next best thing 2Health News:HPV-Linked Oral Cancers on the Rise, Study Finds 2Health News:HPV-Linked Oral Cancers on the Rise, Study Finds 3Health News:Conviction Rates Similar for Suspects of Child, Adult Murder in Utah 2Health News:New research shows $6.7 billion spent on unnecessary tests and treatments in one year 2Health News:Cancer patients in their 60s are tech-savvy 2Health News:Researchers review studies on CCSVI-MS link 2
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Infusion Cannula, 4.0mm....
Subretinal Injection Cannula, Straight; 20g (0.90) x 1" (25mm); Tip Extension: 3mm, 32g (0.23); Angled at 35°....
Medicine Products: